[1] |
CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing.
Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
|
[2] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
[3] |
LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji.
Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
|
[4] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[5] |
CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun.
48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
|
[6] |
CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun.
Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
|
[7] |
LEI Jianlin, WANG Na, WANG Wenzheng, WANG Yan.
One Case of Phenytoin Intoxication Caused by Compound Phenytoin Sodium Ephedrine Hydrochloride and Theophylline Tablets
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 819-822.
|
[8] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[9] |
XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong.
Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
|
[10] |
CAO Weiping, ZHANG Shichao, NI Xia, XIE Bing, WANG Xinzhi, XING Mengtao.
Research Progress in Liver Injury Caused by Drugs Commonly Used during Pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 528-531.
|
[11] |
YANG Jingqi, XU Baohai, ZHANG Jing, JIANG Yang, SHI Fang.
Pharmacovigilance for Traditional Chinese Patent Medicines for Orthopedics
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 436-441.
|
[12] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|
[13] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[14] |
LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan.
Methods for Assessment of MAH Compliance with GVP
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
|
[15] |
ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan.
Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.
|